Enliven Therapeutics(US:ELVN) Prnewswire·2025-12-11 14:00Core Insights - Enliven Therapeutics has appointed Rick Fair as the new Chief Executive Officer, effective December 11, 2025, while co-founder Sam Kintz transitions to Head of Pipeline [1][2][4] - The leadership change is aimed at advancing the company's pivotal Phase 3 trial for ELVN-001 in chronic myeloid leukemia (CML) and enhancing the focus on early pipeline assets [1][4] Company Overview - Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics to improve patient outcomes and address unmet medical needs [5][6] - The company employs a precision oncology approach, leveraging insights into biological targets and differentiated chemistry to create potentially first-in-class or best-in-class therapies [6] Leadership Experience - Rick Fair brings over 25 years of experience in product development and commercialization, including significant roles at Bellicum Pharmaceuticals and Roche/Genentech, where he led the Global Product Strategy for Oncology/Hematology [3] - Fair's expertise includes overseeing the launch of five new therapies and managing a $23 billion business portfolio during his tenure at Roche/Genentech [3] Strategic Focus - The transition in leadership is designed to enhance Enliven's ability to execute a successful Phase 3 trial for ELVN-001, which is expected to begin in 2026 [2][4] - The company aims to deliver long-term value to shareholders through the commercialization of ELVN-001, which is positioned as a potential best-in-class treatment for CML [4]